MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jiac.2026.103047

Медицинская библиотека · Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2026

Twenty-four month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world data from the BICSTaR Japan cohort.

Watanabe Dai, Teruya Katsuji, Yokomaku Yoshiyuki, Minami Rumi, Endo Tomoyuki, Taguchi Nao, Ramroth Johanna, Marongiu Andrea, Thorpe David, Shirasaka Takuma, Oka Shinichi

СтатьяНаблюдательное исследованиеМногоцентровое исследованиеПеревод в очереди

Аннотация

INTRODUCTION

BICSTaR (BICtegravir Single Tablet Regimen) is a multinational observational study assessing the virologic effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with human immunodeficiency virus (HIV). Previously, the 12-month analysis of the Japan cohort of BICSTaR showed high levels of virologic effectiveness and tolerability with B/F/TAF.

METHODS

Data for 84 treatment-experienced (TE) or 116 treatment-naïve (TN) participants aged ≥20 years receiving B/F/TAF as part of routine clinical care in Japan were collected retrospectively and prospectively. Outcomes analyzed at 24 months included HIV-1 RNA <50 copies/mL, treatment persistence, drug-related adverse events (DRAEs), and patient-reported outcomes (prospective cohort only).

RESULTS

At 24 months, 97% of TN and TE participants had HIV-1 RNA <50 copies/mL (missing-equals-excluded analysis), and 96% of participants remained in the study and were receiving B/F/TAF. DRAEs were reported by 14% of participants (TN: 16%; TE: 10%), with diarrhea (TN: 3%; TE: 2%) and weight gain (TN: 4%; TE: 0%) being the most common; the majority of DRAEs occurred in the first 12 months. Participants enrolled prospectively reported stable or improved quality of life through 24 months.

CONCLUSION

Treatment with B/F/TAF in routine HIV clinical care in Japan was associated with high persistence, virologic effectiveness, and was well tolerated through 24 months.

Для цитирования: Watanabe Dai, Teruya Katsuji, Yokomaku Yoshiyuki, Minami Rumi, Endo Tomoyuki, Taguchi Nao, Ramroth Johanna, Marongiu Andrea, Thorpe David, Shirasaka Takuma, Oka Shinichi. Twenty-four month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world data from the BICSTaR Japan cohort.. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2026. DOI: 10.1016/j.jiac.2026.103047.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.